Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker

Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker

Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large numb...

Full description

Bibliographic Details
Main Authors: Diego Signorelli, Patrizia Giannatempo, Giulia Grazia, Marco Maria Aiello, Federica Bertolini, Aurora Mirabile, Sebastiano Buti, Enrico Vasile, Vieri Scotti, Pasquale Pisapia, Maria Silvia Cona, Christian Rolfo, Umberto Malapelle, Immune-Oncology YOUNG Group
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2019/9056417

Internet

http://dx.doi.org/10.1155/2019/9056417

Similar Items